MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa2516505

Медицинская библиотека · The New England journal of medicine · 2026

Azithromycin for Preschoolers with Wheezing in the Emergency Department.

Denninghoff Kurt R, Casper T Charles, Zorc Joseph J, Ruddy Richard M, Satola Sarah, Wendt Wendi-Jo, Morris Claudia R, Tavarez Melissa M, Lipshaw Matthew J, Kwok Maria Y, Nesiama Jo-Ann O, Nelson Kyle A, Webb Michael, Martinez Fernando D, PECARN AZ-SWED Trial Study Group

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Wheezing illnesses are a leading cause of hospitalization for preschool-age children and are frequently treated with antibiotics. Observational studies have shown more frequent isolation of three pathogenic bacteria (Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae) from nasopharyngeal samples from children with recurrent episodes of wheezing than from those without such illnesses.

METHODS

In this multicenter trial, we randomly assigned patients 18 to 59 months of age who presented to an emergency department with a moderate-to-severe episode of wheezing to receive azithromycin once daily at a dose of 12 mg per kilogram of body weight or matching placebo for 5 days. The primary outcome was the sum of scores on the Asthma Flare-up Diary for Young Children (ADYC) over 5 days. Primary-outcome scores could range from 5 to 35, with higher scores indicating more severe wheezing-related symptoms. Efficacy was assessed separately in patients who tested positive for pathogenic bacteria (the positive cohort) and in those who tested negative (the negative cohort). Secondary outcomes were length of stay in the emergency department, length of hospital stay, and return emergency department visits or hospitalizations within 72 hours. Bacterial clearance and antimicrobial resistance were measured at follow-up visits 1 to 3 weeks after randomization.

RESULTS

Among 840 patients who underwent randomization, 521 tested positive for pathogenic bacteria. The trial was stopped for futility by the data and safety monitoring board after a planned interim analysis. ADYC scores did not differ significantly between the azithromycin and placebo groups in either the positive cohort (median, 9.59 [interquartile range, 7.29 to 12.60] vs. 9.72 [interquartile range, 7.66 to 12.17]; P = 0.70) or the negative cohort (median, 9.30 [interquartile range, 6.97 to 11.62] vs. 9.10 [interquartile range, 7.19 to 11.45]; P = 0.69). In the positive cohort, bacterial clearance was 58.7% in the azithromycin group and 11.4% in the placebo group. Secondary outcomes appeared to be similar in the two groups for both cohorts, as did the development of bacterial resistance and the incidence of adverse events.

CONCLUSIONS

Azithromycin did not lead to a greater reduction in the severity of wheezing-related symptoms than placebo in preschool-age children who presented to the emergency department with moderate-to-severe acute wheezing. (Funded by the National Heart, Lung, and Blood Institute and others; AZ-SWED ClinicalTrials.gov number, NCT04669288.).

Для цитирования: Denninghoff Kurt R, Casper T Charles, Zorc Joseph J, Ruddy Richard M, Satola Sarah, Wendt Wendi-Jo, Morris Claudia R, Tavarez Melissa M, Lipshaw Matthew J, Kwok Maria Y, Nesiama Jo-Ann O, Nelson Kyle A, Webb Michael, Martinez Fernando D, PECARN AZ-SWED Trial Study Group. Azithromycin for Preschoolers with Wheezing in the Emergency Department.. The New England journal of medicine. 2026. DOI: 10.1056/nejmoa2516505.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.